HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Choroidal Neovascularization

A pathological process consisting of the formation of new blood vessels in the CHOROID.
Also Known As:
Choroid Neovascularization; Neovascularization, Choroid; Choroid Neovascularizations; Choroidal Neovascularizations; Neovascularization, Choroidal
Networked: 4365 relevant articles (392 outcomes, 673 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Macular Degeneration (Age-Related Maculopathy)
2. Myopia
3. Angioid Streaks
4. Histoplasmosis
5. Degenerative Myopia

Experts

1. Bandello, Francesco: 63 articles (01/2022 - 06/2002)
2. Campochiaro, Peter A: 50 articles (01/2020 - 04/2002)
3. Querques, Giuseppe: 39 articles (01/2022 - 02/2008)
4. Souied, Eric H: 37 articles (03/2022 - 08/2005)
5. Iacono, Pierluigi: 35 articles (03/2021 - 01/2006)
6. Bressler, Neil M: 35 articles (01/2015 - 01/2002)
7. Schmidt-Erfurth, Ursula: 33 articles (03/2021 - 03/2002)
8. Freund, K Bailey: 30 articles (08/2020 - 02/2002)
9. Miller, Joan W: 30 articles (11/2019 - 03/2002)
10. Spaide, Richard F: 30 articles (01/2019 - 02/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Choroidal Neovascularization:
1. Ranibizumab (Lucentis)FDA Link
2. Bevacizumab (Avastin)FDA Link
3. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
4. 1-phenyl-3,3-dimethyltriazene (PDT)IBA
5. Verteporfin (Visudyne)FDA Link
6. Retinaldehyde (Retinal)IBA
7. afliberceptIBA
8. Fluorescein (Funduscein)FDA LinkGeneric
9. pegaptanib (Macugen)FDA Link
10. Indocyanine Green (Cardio-Green)FDA LinkGeneric

Therapies and Procedures

1. Lasers (Laser)
2. Photochemotherapy (Photodynamic Therapy)
3. Intravitreal Injections
4. Therapeutics
5. Injections
01/03/2012 - "After accounting for age, sex, size of choroidal neovascularization, and number of injections, patients who deteriorated in visual acuity at 12 months had significantly larger baseline CRVE, 243.10 μm (95% confidence interval [CI], 227.01-259.19), compared with those who were stable, 214.30 μm (95% CI, 205.79-222.81) and those who improved, 215.26 μm (95% CI, 204.69-225.84; P = 0.007). "
10/23/2020 - "However, independent administration is not enough to completely block the development of choroidal neovascularization (CNV), and the number of eyes vitreous injections is limited. "
01/01/2019 - "Visual acuity, number of injections, PED maximal height and PED area and volume, and choroidal neovascularization (CNV) flow area and progression were determined at each visit. "
01/01/2019 - "Factors independently associated with higher incidence of sustained ≥15-letter loss included age >80 years (odds ratio [OR], 1.33 for patients >80 years vs. ≤80 years; 95% CI, 1.05-1.69; P = 0.02), fewer injections (OR, 0.97 per injection; 95% CI, 0.96-0.98; P = 0.0005), and more visits at which the choroidal neovascularization was graded as active (OR, 1.97 for eyes in upper quartile of active visits vs. eyes in lowest quartile of active visits; 95% CI, 1.39-2.79; P = 0.0001). "
01/01/2018 - "Effect of vitreomacular adhesion (VMA) and ERM on mean treatment interval, number of injections, likelihood of fulfilling the exit criterion, choroidal neovascularization recurrences, CRT decrease, and BCVA improvement. "